Today Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Reported Decrease in Shorted Shares

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

The stock of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) registered a decrease of 1.21% in short interest. BCLI’s total short interest was 1.11M shares in December as published by FINRA. Its down 1.21% from 1.12 million shares, reported previously. With 68,700 shares average volume, it will take short sellers 16 days to cover their BCLI’s short positions. The short interest to Brainstorm Cell Therapeutics Inc’s float is 6.9%.

The stock increased 0.83% or $0.025 during the last trading session, reaching $3.025. About 2,456 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has declined 3.97% since December 6, 2017 and is downtrending. It has underperformed by 19.59% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $62.64 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More notable recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Nasdaq.com which released: “BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND – Nasdaq” on December 04, 2018, also Seekingalpha.com with their article: “BrainStorm granted Japanese Patent for Nurown – Seeking Alpha” published on July 05, 2018, Seekingalpha.com published: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q4 2017 Results – Earnings Call Transcript – Seeking Alpha” on March 10, 2018. More interesting news about Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) were released by: Globenewswire.com and their article: “BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis – GlobeNewswire” published on November 19, 2018 as well as Globenewswire.com‘s news article titled: “BrainStorm Appoints Arturo Araya as Chief Commercial Officer – GlobeNewswire” with publication date: September 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.